Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701526 · ClinicalTrials.gov registry record · Phase 4
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
A Phase 4 study of Migraine, sponsored by H. Lundbeck A/S.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06701526 is a Phase 4 study of Migraine that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 150 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06701526, a Phase 4 study of Migraine, is active but no longer recruiting, sponsored by H. Lundbeck A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Conditions Studied
Interventions
- DRUG Eptinezumab
Study Locations (20)
California
- Neuropain Medical Center - Fresno
- Sunwise Clinical Research, LLC. - Oakland
- The Neuron Clinic - San Marcos
Colorado
- St. Joseph's Hospital and Medical Center - Barrow Neurological Institute - Aurora
- Advanced Neurology of Colorado, LLC - Longmont
- Research of the Rockies - Parker
Massachusetts
- Neurology Center of New England P.C. - Foxborough
- MedVadis Research Corporation - Watertown
- Mass Institute of Clinical Research - Westborough
Connecticut
- Hasbani & Hasbani MDs - New Haven
- New England Institute for Neurology and Headache - Stamford
Florida
- Brainstorm Research - Miami
- Premiere Research Institute at Palm Beach Neurology - West Palm Beach
New York
- Albany Medical College - Albany
- Dent Neurosciences Research Center, Inc. - Amherst
Georgia
- PANDA Neurology and Atlanta Headache Specialists - Atlanta
Idaho
- St Luke's Meridian Medical Center - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06701526
The ClinicalTrials.gov registry entry for NCT06701526 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Eptinezumab is the first listed.
NCT06701526 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06701526 about?
NCT06701526 is a clinical study titled "A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications". The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
What is the current status of trial NCT06701526?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2024-12-18. Estimated completion is 2026-06-05.
What conditions does trial NCT06701526 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06701526?
The interventions under investigation include: Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT06701526?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701526 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.